Skip to navigation Skip to content

Clinical Trial: Immune responses to COVID vaccines in people with MS on ocrelizumab

Share

Details
Type of MS: PPMS|RRMS|SPMS
Treatment mode of action: To determine safety and effectiveness
Number of Subjects: 70
Medication: ocrelizumab
Location: Arizona|Colorado|Connecticut|Kansas|New Jersey|New Mexico|New York|South Dakota|Utah|Wyoming
Institutions: NYU Multiple Sclerosis Center
University of Colorado Anschutz
  Contact Information
Please see below for contact information.

Funding:

Genentech

Description

It is not know whether people receiving ocrelizumab for MS mount adequate immune responses to COVID-19 vaccine. The study is designed to investigate B-cell and T-cell responses to COVID-19 vaccination in patients treated with Ocrevus. 

There are 5 visits for this study. All patients will have their blood drawn prior to their first vaccination, and 4 times following vaccination over the course of 1 year. The immune responses will be analyzed in two research labs at NYU Grossman School of Medicine. We invite people with MS, who have not yet received their COVID vaccination and did not have COVID-19 to participate in this study. More details about the study can be found at clinicaltrias.gov [NCT04843774].

Study sites

NYU Multiple Sclerosis Center
240 East 38th Street, 13th Floor
New York NY 10016
Contact: Katherine Perdomo
929-455-5085
katherine.perdomo@nyulangone.org

University of Colorado Anschutz
13001 E. 17th Place
Aurora, CO 80045
Contact: Neurology Research Partners
303-724-4644  
NeurologyResearchPartners@CUAnschutz.edu
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.